Literature DB >> 9402031

Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium.

S Dunzendorfer1, P Schratzberger, N Reinisch, C M Kähler, C J Wiedermann.   

Abstract

Vascular endothelium activated by endotoxin and cytokines plays an important role in organ inflammation and blood leukocyte recruitment. Neutrophils, which are a homogeneous population of effector cells, are rapidly attracted in large numbers to sites of inflammation where they form an early response to infection or injury. Excessive production of various interleukins, TNF, arachidonic acid metabolites, and other substances by neutrophils and macrophages results in systemic endothelial cell injury, a fundamental problem. In the present study, we investigated in vitro the effects of thalidomide (THD) on activation of endothelial cells for enhanced transmigration of neutrophils by lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF), and interleukin-1 (IL-1). Modulation of endotoxin- and cytokine-induced neutrophil chemotaxis and respiratory burst by THD were also studied. Treatment of HUVEC with THD in combination with LPS, TNF, and IL-1, respectively, antagonized LPS-activated transmigration of neutrophils but stimulated the effects of TNF and IL-1. All of the agents used-THD, LPS, TNF, and IL-1-inhibited neutrophil chemotaxis. Addition of THD to the neutrophils had no effect on LPS-inhibited chemotaxis whereas the TNF- and IL-1-induced chemotaxis was modulated in a bimodal manner. However, THD failed to influence neutrophil respiratory burst activity. Results demonstrate that THD differentially affects mediator-induced activation of HUVEC and neutrophils.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402031     DOI: 10.1007/pl00005087

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  4 in total

1.  Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens.

Authors:  N P Juffermans; A Verbon; M J Schultz; C E Hack; S J van Deventer; P Speelman; T van der Poll
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Potential novel uses of thalidomide: focus on palliative care.

Authors:  V Peuckmann; M Fisch; E Bruera
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

3.  Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

Authors:  Parvaneh Rafiee; Daniel J Stein; Victoria M Nelson; Mary F Otterson; Reza Shaker; David G Binion
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-19       Impact factor: 4.052

4.  The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury.

Authors:  Semih Aydoğan; Ulkü Celiker; Peykan Türkçüoğlu; Nevin Ilhan; Nusret Akpolat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-03       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.